ICU Medical, Inc. (NASDAQ:ICUI) Director Robert S. Swinney sold 1,000 shares of the company’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $215.10, for a total transaction of $215,100.00. Following the completion of the sale, the director now directly owns 13,330 shares of the company’s stock, valued at approximately $2,867,283. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

ICU Medical, Inc. (NASDAQ:ICUI) opened at $213.75 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 4.65. The firm has a market cap of $4,338.13, a PE ratio of 84.51, a price-to-earnings-growth ratio of 3.46 and a beta of 0.33. ICU Medical, Inc. has a 12 month low of $127.00 and a 12 month high of $218.45.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, November 9th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.35. The company had revenue of $343.20 million during the quarter, compared to analyst estimates of $328.56 million. ICU Medical had a net margin of 2.79% and a return on equity of 4.81%. ICU Medical’s revenue was up 253.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.35 earnings per share. equities analysts forecast that ICU Medical, Inc. will post 3.95 EPS for the current year.

A number of brokerages recently issued reports on ICUI. Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $232.00 price objective for the company in a report on Thursday, November 16th. KeyCorp began coverage on shares of ICU Medical in a report on Tuesday, October 17th. They issued a “sector weight” rating for the company. BidaskClub lowered shares of ICU Medical from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Finally, Gabelli reissued a “buy” rating on shares of ICU Medical in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $232.00.

A number of hedge funds have recently made changes to their positions in ICUI. AQR Capital Management LLC boosted its stake in ICU Medical by 4.5% during the first quarter. AQR Capital Management LLC now owns 6,774 shares of the medical instruments supplier’s stock worth $1,034,000 after buying an additional 293 shares during the period. Aperio Group LLC boosted its stake in ICU Medical by 9.7% during the second quarter. Aperio Group LLC now owns 7,521 shares of the medical instruments supplier’s stock worth $1,297,000 after buying an additional 668 shares during the period. US Bancorp DE boosted its stake in ICU Medical by 4.5% during the second quarter. US Bancorp DE now owns 15,705 shares of the medical instruments supplier’s stock worth $2,708,000 after buying an additional 670 shares during the period. Quantitative Systematic Strategies LLC purchased a new position in ICU Medical during the second quarter worth about $233,000. Finally, Parametrica Management Ltd purchased a new position in ICU Medical during the second quarter worth about $213,000. 78.14% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Robert S. Swinney Sells 1,000 Shares of ICU Medical, Inc. (ICUI) Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/30/robert-s-swinney-sells-1000-shares-of-icu-medical-inc-icui-stock.html.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Stock Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related stocks with our FREE daily email newsletter.